| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director, 10% Owner
1 company
Richard E Uihlein is Director, 10% Owner at GALT. Richard E Uihlein's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $149.8M at current prices.
Net of sales, the GALT filings show accumulation of 103,200 shares.
Richard E Uihlein has 17 Form 4 filings on record from December 2017 to July 2026, all as Director, 10% Owner at Galectin Therapeutics (GALT), 2017–2026.
The 33 reported transactions were 11 option or other derivative awards, 9 option exercises, 8 stock awards and 5 open-market purchases.
Counted by filing, the open-market trades come to 4 purchases worth about $477K and no sales.
The largest open-market purchase was 51,500 shares of GALT at an average $4.87 on January 29, 2019, about $251K.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| Sep 4, 2020 | GALT Galectin Therapeutics Inc | Director, 10% Owner | Buy | 10,000 | $2.55 | $25,500.00 | +0.1% | |
| Apr 9, 2019 | GALT Galectin Therapeutics Inc | Director, 10% Owner | Buy | 20,700 | $4.82 | $99,850.59 | +0.8% | |
| Apr 5, 2019 | GALT Galectin Therapeutics Inc | Director, 10% Owner | Buy | 21,000 | $4.81 | $100,972.20 | +0.8% | |
| Jan 29, 2019 | GALT Galectin Therapeutics Inc | Director, 10% Owner | Buy | 51,500 | $4.87 | $250,558.60 | +2.0% |